Stephen Feider Sells 15,018 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Key Points

• CFO Stephen Feider sold 15,018 shares of Beta Bionics (NASDAQ:BBNX) stock for approximately $311,773.68, reducing his ownership by 25.43%.
• Beta Bionics' stock price increased to $22.26, with a 12-month high of $26.66 and a low of $8.89.
• Analysts have a consensus rating of "Moderate Buy" on Beta Bionics, with target prices ranging from $17.00 to $30.00.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 15,018 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $20.76, for a total value of $311,773.68. Following the completion of the transaction, the chief financial officer owned 44,041 shares in the company, valued at $914,291.16. The trade was a 25.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Stephen Feider also recently made the following trade(s):

• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The shares were sold at an average price of $21.00, for a total value of $2,100.00.
• On Tuesday, September 2nd, Stephen Feider sold 1,462 shares of Beta Bionics stock. The stock was sold at an average price of $18.86, for a total transaction of $27,573.32.
• On Friday, August 22nd, Stephen Feider sold 4,413 shares of Beta Bionics stock. The shares were sold at an average price of $17.01, for a total transaction of $75,065.13.
• On Tuesday, August 19th, Stephen Feider sold 5,587 shares of Beta Bionics stock. The shares were sold at an average price of $17.03, for a total transaction of $95,146.61.

Beta Bionics Stock Performance

BBNX traded up $1.77 during trading on Friday, reaching $22.26. The company had a trading volume of 568,463 shares, compared to its average volume of 601,299. Beta Bionics, Inc. has a 12 month low of $8.89 and a 12 month high of $26.66. The business's fifty day moving average price is $19.06 and its 200 day moving average price is $15.74.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.12. The company had revenue of $23.24 million during the quarter, compared to analyst estimates of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

Several research firms have commented on BBNX. Robert W. Baird set a $17.00 target price on Beta Bionics and gave the company a "neutral" rating in a report on Wednesday, July 30th. The Goldman Sachs Group set a $26.00 price objective on Beta Bionics and gave the company a "buy" rating in a research note on Wednesday. Lake Street Capital began coverage on Beta Bionics in a research note on Thursday, June 12th. They set a "buy" rating and a $30.00 target price for the company. Truist Financial increased their target price on shares of Beta Bionics from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Beta Bionics in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.44.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Alyeska Investment Group L.P. purchased a new stake in Beta Bionics in the 1st quarter valued at $918,000. Corebridge Financial Inc. purchased a new position in Beta Bionics in the first quarter worth $79,000. Invesco Ltd. bought a new position in Beta Bionics in the 1st quarter valued at $202,000. Bank of New York Mellon Corp bought a new position in Beta Bionics in the 1st quarter valued at $316,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Beta Bionics during the 1st quarter valued at $1,244,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.